Pharmaceuticals & Therapeutics

In a strategic play, VIVUS is slashing the price of its oral obesity drug QSIVA, challenging the dominance of costly new injectables like Wegovy.

New data reveals Otsuka's VOYXACT clears key markers of kidney damage in IgA nephropathy, offering new hope beyond symptom management for patients.

With $138M in total funding, Endogenex is advancing a novel device that aims to redefine type 2 diabetes treatment by healing the gut, not just managing symptoms.

Biolojic Design's adaptive AI drug for asthma and eczema hits a key milestone with Teva, heralding a new era for personalized autoimmune treatment.

Swedish biotech VERIGRAFT begins a pivotal trial for a personalized, lab-grown vein, offering hope for a true cure for millions with chronic venous insufficiency.

A novel drug, Pegevongitide, enters clinical trials, offering hope against the silent cognitive decline affecting millions undergoing life-saving hemodialysis.

With a top expert at the helm, AltaThera aims to expand its heart rhythm drug for kids, balancing life-saving potential with critical safety warnings.

The scientist behind PARP inhibitors is backing a new approach. Dr. Alan Ashworth's appointment at Leapfrog Bio signals a major push in precision oncology.

The expanded partnership aims to standardize care and meet soaring demand in Northwest Arkansas, integrating two new surgical facilities into the system.

With 35+ years of orthopedic sales experience, Thurman Ballard joins Tetrous to drive adoption of its groundbreaking bone-to-tendon healing technology.

With new financing from Avenue Capital, Turn Therapeutics bets big on its novel skin therapy, GX-03, to tackle multi-billion dollar dermatology markets.

A US-Japan biotech firm secures major funding to advance a first-in-class drug, offering new hope for millions with inherited blood disorders.

The CRDMO giant posted a 16.7% revenue jump in 2025, driven by a massive pipeline expansion and a strategic pivot to next-generation biologics.

A new platform uses AI to turn complex genetic and lifestyle data into an immediate, actionable cancer prevention plan, shifting the paradigm of care.

With positive safety data for its novel UC drug, a €530M cash reserve, and a new commercial chief, Abivax is poised for a major market entry.

With a cash runway into 2027, the biotech firm prepares for critical data on its innovative bispecific antibody pipeline for hard-to-treat solid tumors.

A new collaboration aims to solve antibody reproducibility, promising to enhance diagnostic accuracy and accelerate the future of precision oncology.

The bioconjugate CRDMO reports record profits and a $1.49B backlog, fueled by tech innovation, strategic acquisitions, and global expansion.

With major expansions in the US and Europe, Cambrex aims to lead the high-stakes race for specialized API production, targeting next-generation therapies.

With a promising non-opioid drug and new leadership known for major deals, Persica Pharmaceuticals is poised to revolutionize back pain treatment.